This video highlights a study that establishes mutated CALR as a myeloproliferative neoplasms–specific tumor antigen and provides a rationale for the development of immunotherapies targeting mutated CALR.
This video highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.
This video reviews the phase I portion of a trial testing glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.
Survival of patients with myelofibrosis who undergo splenectomy is adversely affected by older age, the need for transfusion, and leukocyte and circulating blast cell counts, according to a new analysis.
A new study including two separate cohorts found that male gender is a significant risk factor for mortality in patients with essential thrombocythemia. Gender may play a bigger role than thrombosis history in determining risk.
Myeloproliferative Neoplasms: Translating New Discoveries Into Better Outcomes, Better Quality of Life
In this review, we demonstrate the evolving landscape of clinical investigation as researchers and clinicians attempt to address the important therapeutic needs of patients with myeloproliferative neoplasms.
Patients with myelofibrosis resistant or intolerant to ruxolitinib may have an alternative treatment option with the JAK2-selective inhibitor fedratinib, according to the results of a phase II study.
The JAK2 and FLT3 inhibitor pacritinib induced significant and sustained spleen volume reduction and symptom reduction in patients with myelofibrosis.
In this interview we discuss clinical developments in essential thrombocythemia, polycythemia vera, and myelofibrosis, as well as the latest treatment options.
A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis
A 60-year-old man with a history of coronary artery disease and JAK2 V617F–positive polycythemia vera presented to our bone marrow transplantation clinic with progressive fatigue, splenomegaly, and cytopenias.